HOLON, Israel, June 17,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq:
CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company
and a pioneer in computational target discovery,
today announced that Pierre Ferré, Ph.D, SVP, Preclinical
Development and Corporate Operations, Compugen will present a case
study on clinical dose selection for TIGIT monospecific and
bispecific antibodies at the Antibody Industrial Symposium taking
place June 20-21, 2024, Montpellier,
France.
Event: 12th Antibody Industrial
Symposium, Montpellier, France
Date: Friday, June 21, 2024
Presenter: Pierre Ferré, Ph.D., SVP, Preclinical
Development and Corporate Operations, Compugen
Presentation title: Case study on clinical dose selection
for TIGIT monospecific and bispecific antibodies
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a
PD-1/TIGIT bispecific antibody where the TIGIT component is derived
from Compugen's clinical stage anti-TIGIT antibody, COM902, is in
Phase 3 development by AstraZeneca through a license agreement for
the development of bispecific and multispecific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance, of which
the most advanced program, COM503, in IND enabling studies is
licensed to Gilead. COM503 is a potential first-in-class, high
affinity antibody which blocks the interaction between IL-18
binding protein and IL-18, thereby freeing natural IL-18 in the
tumor microenvironment to inhibit cancer growth. Compugen is
headquartered in Israel, with
offices in San Francisco, CA.
Compugen's shares are listed on Nasdaq and the Tel Aviv Stock
Exchange under the ticker symbol CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-at-upcoming-antibody-industrial-symposium-302174100.html
SOURCE Compugen Ltd.